Generic Name and Formulations:
Pregabalin 20mg/mL.
Company:
Pfizer Inc.
Indications for LYRICA ORAL SOLUTION:
Fibromyalgia.
Adult:
≥18yrs: initially 75mg twice daily, may increase to 150mg twice daily within 1 week as tolerated; max 450mg/day. Renal impairment (CrCl <60mL/min): reduce dose (see literature); hemodialysis: give supplemental dose after session.
Children:
<18yrs: not recommended.
Warnings/Precautions:
Avoid abrupt cessation (taper over ≥1 week). Discontinue if angioedema, hypersensitivity reactions, myopathy or markedly elevated creatine kinase levels occur. CHF. Ocular conditions. Diabetes (monitor skin integrity). Suicidal tendencies (monitor). Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
Interactions:
Potentiates CNS depression with alcohol, other CNS depressants. Additive edema, weight gain with thiazolidinediones.
See Also:
LYRICA
Pharmacological Class:
alpha2-delta ligand.
Adverse Reactions:
Dizziness, somnolence, other CNS effects, dry mouth, edema, ocular/visual effects (eg, blurring), weight gain, thinking abnormal (primarily difficulty with concentration/attention), infection, asthenia, paresthesias, elevated creatine kinase, decreased platelets, arrhythmias (PR prolongation); male-mediated teratogenicity; may be tumorigenic.
How Supplied:
Caps—90; Soln—16oz
Indications for LYRICA ORAL SOLUTION:
Neuropathic pain associated with diabetic peripheral neuropathy (DPN) or spinal cord injury. Postherpetic neuralgia (PHN).
Adult:
≥18yrs: DPN: initially 50mg 3 times daily, may increase to 100mg 3 times daily within 1 week. Spinal cord injury: initially 75mg twice daily, may increase to 150mg twice daily within 1 week, then max 600mg/day after 2 weeks as tolerated. PHN: initially 75mg twice daily or 50mg 3 times daily; max 300mg/day after 1 week then 600mg/day after 2 weeks as tolerated (see literature). For all: renal impairment (CrCl <60mL/min): reduce dose (see literature); hemodialysis: give supplemental dose after session.
Children:
<18yrs: not recommended.
Warnings/Precautions:
Avoid abrupt cessation (taper over ≥1 week). Discontinue if angioedema, hypersensitivity reactions, myopathy or markedly elevated creatine kinase levels occur. CHF. Ocular conditions. Diabetes (monitor skin integrity). Suicidal tendencies (monitor). Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
Interactions:
Potentiates CNS depression with alcohol, other CNS depressants. Additive edema, weight gain with thiazolidinediones.
See Also:
LYRICA
Pharmacological Class:
alpha2-delta ligand.
Adverse Reactions:
Dizziness, somnolence, other CNS effects, dry mouth, edema, ocular/visual effects (eg, blurring), weight gain, thinking abnormal (primarily difficulty with concentration/attention), infection, asthenia, paresthesias, elevated creatine kinase, decreased platelets, arrhythmias (PR prolongation); male-mediated teratogenicity; may be tumorigenic.
How Supplied:
Caps—90; Soln—16oz
Indications for LYRICA ORAL SOLUTION:
Adjunct in partial onset seizures.
Adult:
≥18yrs: Give in 2–3 divided doses. Initially 150mg/day, max 600mg/day. Renal impairment (CrCl <60mL/min): reduce dose (see literature); hemodialysis: give supplemental dose after session.
Children:
<18yrs: not recommended.
Warnings/Precautions:
Avoid abrupt cessation (taper over ≥1 week). Discontinue if angioedema, hypersensitivity reactions, myopathy or markedly elevated creatine kinase levels occur. CHF. Ocular conditions. Diabetes (monitor skin integrity). Suicidal tendencies (monitor). Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
Interactions:
Potentiates CNS depression with alcohol, other CNS depressants. Additive edema, weight gain with thiazolidinediones.
See Also:
LYRICA
Pharmacological Class:
alpha2-delta ligand.
Adverse Reactions:
Dizziness, somnolence, other CNS effects, dry mouth, edema, ocular/visual effects (eg, blurring), weight gain, thinking abnormal (primarily difficulty with concentration/attention), infection, asthenia, paresthesias, elevated creatine kinase, decreased platelets, arrhythmias (PR prolongation); male-mediated teratogenicity; may be tumorigenic.
How Supplied:
Caps—90; Soln—16oz
